Title: Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells.
Journal: Toxicology and applied pharmacology 20170415
Title: Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Journal: Journal of medicinal chemistry 20160728
Title: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
Journal: Journal of hematology & oncology 20160101
Title: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Journal: The Lancet. Oncology 20150901
Title: Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era?
Journal: Drug design, development and therapy 20150101
Title: Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Journal: Cancer discovery 20131201
Title: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20130201
Title: Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25.
